Physician profile
Jeevan Pai
NPI 1851312870
$4,293.22
in general payments reported to CMS, 2019-2025
26 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $35.20 · 2021: $18.26 · 2022: $499 · 2023: $1,235 · 2024: $1,271 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,553 · Education: $67.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,552.80 |
| Education | $67.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,516.09 | 2020-2025 | |
| Pfizer INC. | $395.28 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.48 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $265.05 | 2023-2025 | Tremfya, Stelara |
| Celgene Corporation | $247.02 | 2022-2024 | Zeposia |
| Genzyme Corporation | $203.56 | 2022-2025 | |
| Qol Medical, LLC | $192.88 | 2022-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $192.09 | 2019-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $125.35 | 2022-2024 | Dupixent |
| Celltrion USA INC. | $91.37 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Ferring Pharmaceuticals INC. | $90.99 | 2019-2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $84.30 | 2022-2025 | Ocaliva |
| Lilly USA, LLC | $82.45 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $76.07 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $71.35 | 2024-2025 | Zenpep |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $68.02 | 2023-2024 | |
| Endogastric Solutions, INC | $54.75 | 2024 | Esophyx |
| Daiichi Sankyo INC. | $45.33 | 2021-2022 | |
| Intra-Sana Laboratories | $36.42 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.92 | 2023 | Cyltezo |
| Organon LLC | $29.16 | 2023 | Hadlima |
| Ardelyx, INC. | $28.63 | 2022-2023 | Ibsrela |
| Madrigal Pharmaceuticals | $20.83 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $18.20 | 2024 | Bylvay |
| Braintree Laboratories, INC. | $14.58 | 2023 | Sutab |
| Nestle Healthcare Nutrition INC. | $14.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeevan Pai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.